ResMed Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ResMed Inc. (NYSE: RMD; ASX: RMD) develops, manufactures, distributes and markets cloud-connected medical devices, digital health technologies and software platforms that diagnose, treat and manage sleep-disordered breathing, chronic obstructive pulmonary disease (COPD), respiratory insufficiency and other chronic diseases. The company offers continuous positive airway pressure (CPAP) and automatic positive airway pressure (APAP) devices including the AirSense and Air11 series; masks and accessories such as the AirFit, AirTouch N30i and F30i fabric-based platforms; ventilators like the Lumis series for non-invasive support; humidifiers including HumidCare; portable options such as AirMini; and software solutions encompassing myAir for patient self-monitoring, AirView for remote clinician oversight, and SaaS platforms for out-of-hospital care providers including residential care management tools. It operates through two primary segments: Sleep and Respiratory Care, addressing obstructive sleep apnea, central sleep apnea, overlap syndrome, obesity hypoventilation and neuromuscular diseases; and Software as a Service (SaaS), supporting healthcare professionals with data-driven platforms. ResMed serves patients, clinicians, sleep labs, homecare providers and health systems in over 140 countries, with key growth markets in the United States, Canada, Latin America, Europe, China, South Korea, India, Brazil and Eastern Europe. Founded in 1989 by Dr. Peter Farrell in Sydney, Australia, to commercialize CPAP technology, the company is headquartered in San Diego, California, and employs approximately 10,600 people. Recent developments include the May 2025 acquisition of VirtuOx, a leading independent diagnostic testing facility for at-home sleep, respiratory and cardiac testing, which operates as a wholly owned subsidiary to streamline diagnostics, enhance virtual care coordination and expand into adjacent areas like insomnia; launches of new AirTouch F30i mask variants including the comfort edition in Australia and clear edition in the U.S.; strategic U.S. manufacturing and distribution expansion in Indianapolis; and a board leadership change with director Richard Sulpizio departing following the 2025 annual stockholders' meeting.
Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?
The Hidden 401(k) Tax Bomb That Hits a $1.3 Million Saver With $19,800 in Their First RMD Year
The In Plan Roth 401(k) Conversion That Saves a $400,000 Earner $58,000 in Future RMD Taxes
Is the Options Market Predicting a Spike in ResMed Stock?
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
A Look at ResMed Inc (RMD) After 3.9% Decline -- GF Value $270.01 vs Price $198.76
10 Dividend Growth Stocks: May 2025
Here's Why ResMed (RMD) is a Strong Growth Stock
RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
ResMed Inc (RMD) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
ResMed (RMD) Reports Q3 Earnings: What Key Metrics Have to Say
ResMed (RMD) Surpasses Q3 Earnings and Revenue Estimates
ResMed beats quarterly profit estimates, names new CFO
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor